rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Viridian Therapeutics, Inc.

VRDN · Nasdaq

Health CareBiotechnologyAbove a falling average

VRDN stood above a rising 150-day average in 22 of the last 52 weekly readings, and has been out of that trend for the last 30 weeks. It is 7.7% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 30
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$50.0M
Insider sales, 12 months
$838K
Officials’ trades on record
0
Institutions holding
204 (-11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$38.5MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months2
Buyers · sellers3 · 1
WhoDidSharesTraded
Jennifer TousignantChief Legal Officersold4,212at $24.5019 Aug 2026filed 20 Aug 2026
Jennifer TousignantChief Legal Officersold10,000at $24.5019 Aug 2026filed 20 Aug 2026
Fairmount Funds Management LlcDirector, 10% ownerbought1,176,470at $17.0011 May 2026filed 13 May 2026
Jennifer TousignantChief Legal Officersold2,272at $31.1631 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders204-11 on the quarter
New · exited46 · 57
Reported value$2.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202616,604,740$305.0M+1,225,363+8.0%
BlackRock, Inc.added · filed 7 Aug 20268,551,488$157.1M+720,013+9.2%
Bellevue Group AGadded · filed 14 Aug 20266,731,909$123.7M+5,765+0.1%
Paradigm Biocapital Advisors LPadded · filed 14 Aug 20266,723,788$123.5M+3,574,895+113.5%
Kynam Capital Management, LPadded · filed 14 Aug 20266,453,877$118.6M+4,112,225+175.6%
STATE STREET CORPadded · filed 7 Aug 20266,124,976$112.5M+1,452,091+31.1%
Fairmount Funds Management LLCadded · filed 14 Aug 20265,090,928$93.5M+1,176,470+30.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,576,860$84.1M+409,659+9.8%
Deep Track Capital, LPadded · filed 14 Aug 20263,592,740$66.0M+2,198,796+157.7%
Venrock Adviser, LLCreduced · filed 14 Aug 20263,257,917$59.8M-624,792−16.1%
31 Mar 2023 – 30 Jun 2026
111161211Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jennifer Tousignant Company insiderChief Legal Officer · last 19 Aug 20260 · 2
Radhika Tripuraneni Company insiderChief Medical Officer · last 14 Aug 20260 · 0
Arlene Morris Company insiderDirector · last 1 Jul 20260 · 0
Christopher W. Cain Company insiderDirector · last 1 Jul 20260 · 0
Jeffrey Robert Ajer Company insiderDirector · last 1 Jul 20260 · 0
Jennifer K. Moses Company insiderDirector · last 1 Jul 20260 · 0
Sarah Gheuens Company insiderDirector · last 1 Jul 20260 · 0
Tomas Kiselak Company insiderDirector · last 1 Jul 20260 · 0
Fairmount Funds Management LLC Company insiderDirector, 10% owner · last 11 May 20261 · 0
Fairmount Healthcare Fund Ii L.p. Company insiderDirector, 10% owner · last 11 May 20263 · 0
Seth Harmon Company insiderChief Financial Officer · last 3 Mar 20260 · 0
Stephen F. Mahoney Company insiderPresident and CEO · last 3 Mar 20261 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-513%
Free cash flow marginFY 2025 · to 31 Dec 2025-391%
Return on capital employedFY 2025 · to 31 Dec 2025-43.9%
Share count trendFY 2025 · to 20 Feb 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$212.4M
Free cash flowFY 2025 · to 31 Dec 2025−$276.9M

Analyst forecasts

No analyst forecasts yet.